Biodexa Pharmaceuticals Plc ADR (BDRX)

$1.63 -0.07 (-4.12%)
Market Cap 1.10M
Revenue (ttm) 0.00
Net Income (ttm) -7.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.04
Volume 81,700
Avg Vol 1,298,032
Day's Range N/A - N/A
Shares Out 620,000.00
Stochastic %K 4%
Beta 0.95
Analysts Strong Buy
Price Target $18.00

Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 29 2048 0180
Address:
1 Caspian Point, Caspian Way, Cardiff, United Kingdom
Darkswede
Darkswede Feb. 3 at 8:59 PM
$BDRX getting close to ATM again. The crooks.
0 · Reply
Newbegininngs
Newbegininngs Feb. 3 at 7:29 PM
$BDRX How low can we go??
1 · Reply
TATTED_KEN
TATTED_KEN Feb. 3 at 1:29 PM
$BDRX $LGHL my current tickers I’m holding. Watching $AREB to enter
1 · Reply
LazyDonut2022
LazyDonut2022 Feb. 2 at 9:22 PM
$BDRX $SLS man
1 · Reply
Love_To_Learn
Love_To_Learn Feb. 2 at 9:19 PM
$BDRX if u think your bid n ask on batman n robin is coincidence u r sadly mistaking
0 · Reply
cb5000calls
cb5000calls Feb. 2 at 9:15 PM
$SLS SLS runs first → eyes come to the sector → money rotates into beaten-down biotechs → PULM first, BDRX last SLS is leading with strength, PULM is coiled, BDRX is lagging — exactly how a Batman/Robin basket is supposed to look. @Love_To_Learn is this correct? Charts line up with the Batman/Robin take. SLS already broke trend and is consolidating on volume — leader behavior. PULM basing post-flush, BDRX still lagging. If capital rotates, order matters. $BDRX $PULM
2 · Reply
Love_To_Learn
Love_To_Learn Feb. 2 at 9:02 PM
$BDRX coding batman robin $SLS $PULM
0 · Reply
Love_To_Learn
Love_To_Learn Feb. 2 at 3:38 PM
$BDRX HIDING THE 1.68 IN TH SPREAD
0 · Reply
Love_To_Learn
Love_To_Learn Feb. 2 at 3:38 PM
$BDRX EXECUTING BATMAN ROBIN $PULM
1 · Reply
Love_To_Learn
Love_To_Learn Feb. 2 at 2:56 PM
$BDRX CONTINUING TO LOWER U
0 · Reply
Latest News on BDRX
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

Jan 5, 2026, 8:30 AM EST - 4 weeks ago

Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

Biodexa Announces Pricing of $10 Million Public Offering

Dec 18, 2025, 8:30 AM EST - 6 weeks ago

Biodexa Announces Pricing of $10 Million Public Offering

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

Dec 1, 2025, 8:30 AM EST - 2 months ago

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

Nov 24, 2025, 8:30 AM EST - 2 months ago

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Nov 3, 2025, 8:30 AM EST - 3 months ago

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Oct 6, 2025, 8:30 AM EDT - 4 months ago

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Interim results for the six months ended June 30, 2025

Sep 12, 2025, 8:30 AM EDT - 5 months ago

Interim results for the six months ended June 30, 2025

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Sep 8, 2025, 7:00 AM EDT - 5 months ago

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Aug 18, 2025, 8:30 AM EDT - 6 months ago

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

ADR Ratio Change Effective

Jul 31, 2025, 9:30 AM EDT - 6 months ago

ADR Ratio Change Effective

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

Jul 28, 2025, 7:00 AM EDT - 6 months ago

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

ADR Ratio Change

Jul 15, 2025, 4:30 PM EDT - 7 months ago

ADR Ratio Change

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jul 14, 2025, 8:30 AM EDT - 7 months ago

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Results of Annual General Meeting

Jun 27, 2025, 8:30 AM EDT - 7 months ago

Results of Annual General Meeting

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jun 25, 2025, 8:30 AM EDT - 7 months ago

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Jun 23, 2025, 8:30 AM EDT - 8 months ago

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Jun 18, 2025, 7:00 AM EDT - 8 months ago

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Result of General Meeting

Jun 11, 2025, 4:30 PM EDT - 8 months ago

Result of General Meeting

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Jun 4, 2025, 8:30 AM EDT - 8 months ago

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Shareholder Update

May 30, 2025, 8:30 AM EDT - 8 months ago

Shareholder Update

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

May 22, 2025, 4:30 PM EDT - 9 months ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

May 22, 2025, 8:30 AM EDT - 9 months ago

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

May 12, 2025, 8:30 AM EDT - 9 months ago

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

Notice of General Meeting

Apr 17, 2025, 8:30 AM EDT - 10 months ago

Notice of General Meeting

Preliminary Results for the Year Ended 31 December 2024

Apr 11, 2025, 8:30 AM EDT - 10 months ago

Preliminary Results for the Year Ended 31 December 2024

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Mar 19, 2025, 7:00 AM EDT - 11 months ago

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Mar 10, 2025, 8:30 AM EDT - 11 months ago

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Mar 6, 2025, 8:30 AM EST - 11 months ago

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Feb 24, 2025, 8:30 AM EST - 1 year ago

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Feb 13, 2025, 8:30 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Feb 12, 2025, 7:30 AM EST - 1 year ago

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Feb 10, 2025, 8:30 AM EST - 1 year ago

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Jan 22, 2025, 8:30 AM EST - 1 year ago

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Nov 21, 2024, 7:35 AM EST - 1 year ago

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Nov 12, 2024, 8:48 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Oct 31, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Oct 30, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Oct 29, 2024, 10:00 AM EDT - 1 year ago

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Oct 28, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

Oct 27, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

Darkswede
Darkswede Feb. 3 at 8:59 PM
$BDRX getting close to ATM again. The crooks.
0 · Reply
Newbegininngs
Newbegininngs Feb. 3 at 7:29 PM
$BDRX How low can we go??
1 · Reply
TATTED_KEN
TATTED_KEN Feb. 3 at 1:29 PM
$BDRX $LGHL my current tickers I’m holding. Watching $AREB to enter
1 · Reply
LazyDonut2022
LazyDonut2022 Feb. 2 at 9:22 PM
$BDRX $SLS man
1 · Reply
Love_To_Learn
Love_To_Learn Feb. 2 at 9:19 PM
$BDRX if u think your bid n ask on batman n robin is coincidence u r sadly mistaking
0 · Reply
cb5000calls
cb5000calls Feb. 2 at 9:15 PM
$SLS SLS runs first → eyes come to the sector → money rotates into beaten-down biotechs → PULM first, BDRX last SLS is leading with strength, PULM is coiled, BDRX is lagging — exactly how a Batman/Robin basket is supposed to look. @Love_To_Learn is this correct? Charts line up with the Batman/Robin take. SLS already broke trend and is consolidating on volume — leader behavior. PULM basing post-flush, BDRX still lagging. If capital rotates, order matters. $BDRX $PULM
2 · Reply
Love_To_Learn
Love_To_Learn Feb. 2 at 9:02 PM
$BDRX coding batman robin $SLS $PULM
0 · Reply
Love_To_Learn
Love_To_Learn Feb. 2 at 3:38 PM
$BDRX HIDING THE 1.68 IN TH SPREAD
0 · Reply
Love_To_Learn
Love_To_Learn Feb. 2 at 3:38 PM
$BDRX EXECUTING BATMAN ROBIN $PULM
1 · Reply
Love_To_Learn
Love_To_Learn Feb. 2 at 2:56 PM
$BDRX CONTINUING TO LOWER U
0 · Reply
thatboytrades
thatboytrades Feb. 2 at 6:29 AM
$LGHL $BDRX paytience
0 · Reply
MOisLovetolearnandJOKA
MOisLovetolearnandJOKA Jan. 31 at 6:51 AM
$BDRX $PSTV funny that clown mo @Love_To_Learn and @joka2189 (same guy) told to people that he is here for help old followers lmao after 7 years waiting and everybfollowers lost everything in his beaud and beloved. They need 1000 per share to break evern lol momo pat willianson hungryearner retarded guy
0 · Reply
MOisLovetolearnandJOKA
MOisLovetolearnandJOKA Jan. 30 at 3:15 PM
$BDRX another great calle of mo @Love_To_Learn always inverse King midas.
0 · Reply
Naif_si
Naif_si Jan. 30 at 1:16 PM
$BDRX is there news coming??
1 · Reply
Love_To_Learn
Love_To_Learn Jan. 29 at 8:54 PM
$BDRX OLD PRPO 1.8,1.86(1.89)(1.91**) DETONATION SEQUENCE
2 · Reply
Love_To_Learn
Love_To_Learn Jan. 29 at 8:54 PM
$BDRX CREATING DETONATION SEQUENCE FOR MARKET OFF 1.91*
0 · Reply
Darkswede
Darkswede Jan. 29 at 7:59 PM
$BDRX scam continues 10 years and pumpers post BS here.
0 · Reply
fisher04
fisher04 Jan. 29 at 4:48 PM
$BDRX whole market get wrecked. we will be good soon .
0 · Reply
TATTED_KEN
TATTED_KEN Jan. 29 at 4:31 PM
$BDRX buying the dip. No reason why we should be down
0 · Reply
Newbegininngs
Newbegininngs Jan. 29 at 4:04 PM
$BDRX what's happening today? 😬
0 · Reply
Bigpaulbunyon
Bigpaulbunyon Jan. 29 at 3:08 PM
$BDRX do we really have a marketcap of just over $1 million ??
1 · Reply
fisher04
fisher04 Jan. 29 at 1:28 PM
$BDRX soon .
0 · Reply